Cervical cancer Cancer Cervical cancer
Conditions
Interventions
Chemotherapy patients randomised to chemotherapy, will receive this treatment prior to local therapy. Chemotherapy will consist of: cisplatin (50 mg/m^2), methotrexate (100 mg/m^2) and folinic acid (1
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically proven invasive cancer of the cervix Stage Ib through to IVa 2. Patients must be fit enough to receive adjuvant chemotherapy, and the chosen definitive treatment 3. World Health Organisation (WHO) performance status zero to one or creatinine clearance of at least 60 ml/min 4. The informed consent of the patient
Exclusion criteria
Exclusion criteria: 1. Previous chemotherapy 2. Renal, hepatic or bone marrow dysfunction which in the opinion of the investigator is sufficient to prejudice therapy (including local treatment and chemotherapy 3. Previous malignancy other than basal cell carcinoma 4. Medical or psychological conditions precluding treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival and time to recurrence | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed